CGIX - キャンサ―・ジェネティクス (Cancer Genetics Inc.) キャンサ―・ジェネティクス

 CGIXのチャート


 CGIXの企業情報

symbol CGIx
会社名 Cancer Genetics Inc. (キャンサ―・ジェネティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical Specialities  
業種 ヘルスケア施設_サ―ビス   医療関連(Health Care)
概要 事業概要 キャンサー・ジェネティクス(Cancer Genetics Inc)は米国ベースの診断会社である。同社は癌の診断、予後と治療への応答を改善するためにゲノムテストと関連サービスの開発・商業化を中心に行っている。これらの癌は血液、尿生殖器及びヒトパピローマウイルス(HPV)に関連する癌を含む。同社は病院、がんセンター、医師のオフィスで腫瘍医や病理医にそのテストとサービスを提供する。同社はマイクロアレイとプローブの2種類のデオキシリボ核酸(DNA)ベースのゲノムテストを開発・生産している。同社は慢性リンパ性白血病(CLL)のためのマイクロアレイ試験である「MatBA-CLL」を提供し、その腫瘍学市場で他のゲノムテストを開発している。同社はイタリアのミラノに事務所を有している。   キャンサ―・ジェネティクスは、米国のがん診断製品開発会社。がん治療のための診断、予後診断、また個人に特化するゲノム検査やサ―ビスの開発、商品化を手掛ける。がん専門医や病理学者、がんセンタ―、診療所のほか、バイオ製薬企業や臨床研究機関を対象に、一般の腫瘍学向け検査や研究サ―ビスとともにゲノム検査およびサ―ビスを提供する。   
本社所在地 201 Route 17 North 2nd Floor Rutherford NJ 07070 USA
代表者氏名 John A. Roberts ジョンA.ロバーツ
代表者役職名 President Chief Executive Officer
電話番号 +1 201-528-9200
設立年月日 36251
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 245人
url www.cancergenetics.com
nasdaq_url https://www.nasdaq.com/symbol/cgix
adr_tso
EBITDA EBITDA(百万ドル) -20.73900
終値(lastsale) 0.9099
時価総額(marketcap) 25246537.6203
時価総額 時価総額(百万ドル) 22.89086
売上高 売上高(百万ドル) 30.25400
企業価値(EV) 企業価値(EV)(百万ドル) 31.61386
当期純利益 当期純利益(百万ドル) -1.41800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cancer Genetics Inc revenues increased 8% to $14.7M. Net loss decreased 34% to $8.1M. Revenues reflect Revenue Discovery Services increase from $556K to $3M Revenue Biopharma Services increase of 3% to $7.2M. Lower net loss reflects Change in fair value of warrant liabilit increase from $6.7M (expense) to $2.8M (income) Research and Development - decrease of 34% to $1.3M (expense).

 CGIXのテクニカル分析


 CGIXのニュース

   Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright  2021/01/07 21:05:00 GlobeNewswire
RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery…
   Cancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 Million  2020/10/29 01:55:00 GlobeNewswire
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical…
   CANCER GENETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cancer Genetics, Inc. - CGIX  2020/08/26 22:09:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cancer Genetics, Inc. (NasdaqGS: CGIX) with StemoniX, Inc. in a stock-for-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that this transaction undervalues the Company and/or if you wo
   The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout  2020/08/25 12:38:16 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDAQ: PRNB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Revance Therapeutics Inc (NASDAQ: RVNC ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) (FDA granted a third fast-track designation to its lead drug candidate, repotrectinib) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 24) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Kymera Therapeutics Inc (NASDAQ: KYMR ) (IPOed Friday) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Polypid Ltd (NASDAQ: PYPD ) Poseida Therapeutics, Inc. (NASDAQ: PSTX ) Recro Pharma Inc (NASDAQ: REPH ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Tricida Inc (NASDAQ: TCDA ) (FDA rejected its drug to treat metabolic acidosis and requested additional data) Unity Biotechnology Inc (NASDAQ: UBX ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Qiagen Launches Rapid …
   Cancer Genetics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Cancer Genetics, Inc. is Fair to Shareholders; Investors are Encouraged to Contact the Firm  2020/08/25 10:20:00 PR Newswire
NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Cancer Genetics, Inc. (NASDAQ: CGIX) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection…
   Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright  2021/01/07 21:05:00 GlobeNewswire
RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery…
   Cancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 Million  2020/10/29 01:55:00 GlobeNewswire
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical…
   CANCER GENETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cancer Genetics, Inc. - CGIX  2020/08/26 22:09:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cancer Genetics, Inc. (NasdaqGS: CGIX) with StemoniX, Inc. in a stock-for-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that this transaction undervalues the Company and/or if you wo
   The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout  2020/08/25 12:38:16 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDAQ: PRNB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Revance Therapeutics Inc (NASDAQ: RVNC ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) (FDA granted a third fast-track designation to its lead drug candidate, repotrectinib) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 24) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Kymera Therapeutics Inc (NASDAQ: KYMR ) (IPOed Friday) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Polypid Ltd (NASDAQ: PYPD ) Poseida Therapeutics, Inc. (NASDAQ: PSTX ) Recro Pharma Inc (NASDAQ: REPH ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Tricida Inc (NASDAQ: TCDA ) (FDA rejected its drug to treat metabolic acidosis and requested additional data) Unity Biotechnology Inc (NASDAQ: UBX ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Qiagen Launches Rapid …
   Cancer Genetics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Cancer Genetics, Inc. is Fair to Shareholders; Investors are Encouraged to Contact the Firm  2020/08/25 10:20:00 PR Newswire
NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Cancer Genetics, Inc. (NASDAQ: CGIX) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection…
   Cancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 Million  2020/10/29 01:55:00 GlobeNewswire
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical…
   CANCER GENETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cancer Genetics, Inc. - CGIX  2020/08/26 22:09:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cancer Genetics, Inc. (NasdaqGS: CGIX) with StemoniX, Inc. in a stock-for-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that this transaction undervalues the Company and/or if you wo
   The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout  2020/08/25 12:38:16 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDAQ: PRNB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Revance Therapeutics Inc (NASDAQ: RVNC ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) (FDA granted a third fast-track designation to its lead drug candidate, repotrectinib) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 24) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Kymera Therapeutics Inc (NASDAQ: KYMR ) (IPOed Friday) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Polypid Ltd (NASDAQ: PYPD ) Poseida Therapeutics, Inc. (NASDAQ: PSTX ) Recro Pharma Inc (NASDAQ: REPH ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Tricida Inc (NASDAQ: TCDA ) (FDA rejected its drug to treat metabolic acidosis and requested additional data) Unity Biotechnology Inc (NASDAQ: UBX ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Qiagen Launches Rapid …
   Cancer Genetics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Cancer Genetics, Inc. is Fair to Shareholders; Investors are Encouraged to Contact the Firm  2020/08/25 10:20:00 PR Newswire
NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Cancer Genetics, Inc. (NASDAQ: CGIX) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection…
   Why Cancer Genetics Is Trading Higher Today  2020/08/24 19:41:58 Benzinga
Cancer Genetics (NASDAQ: CGIX ) shares are trading higher on Monday after the company announced the entry into a definitive merger agreement with StemoniX. Cancer Genetics is in the early stage of precision medicine, enabling individualized therapies in the field of oncology through diagnostic products and services and molecular … Full story available on Benzinga.com

 関連キーワード  (ヘルスケア施設_サ―ビス 米国株 キャンサ―・ジェネティクス CGIX Cancer Genetics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)